Abualbishr Alshreef
Sheffield, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US.
Journal: Future oncology (London, England)
Published: February 27, 2026
Approaches to modeling treatment sequencing in practice: a thematic review of prior NICE appraisals.
Approaches to modeling treatment sequencing in practice: a thematic review of prior NICE appraisals.
Journal: International journal of technology assessment in health care
Published: November 26, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: October 24, 2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.
Journal: Future oncology (London, England)
Published: October 21, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 13, 2025
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma.
Journal: Future oncology (London, England)
Published: August 13, 2025
Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 09, 2025
Assessing Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Simulation Study.
Journal: Medical decision making : an international journal of the Society for Medical Decision Making
Published: November 09, 2024
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.
Journal: PharmacoEconomics
Published: June 20, 2021
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Journal: Health technology assessment (Winchester, England)
Published: June 16, 2021
Last Updated: 09/26/2026